Travere Therapeutics Inc. has announced that on May 10, 2025, its Compensation Committee granted inducement equity grants to six new employees. These grants consist of restricted stock units (RSUs) covering a total of 35,900 shares of Travere's common stock. The RSUs are issued under the terms of Travere's 2018 Equity Incentive Plan, although they were granted outside of this plan as inducements for the new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting on each anniversary of the grant date, contingent upon the employees' continued service with Travere.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.